BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22292935)

  • 1. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
    Shi J; Yao D; Liu W; Wang N; Lv H; Zhang G; Ji M; Xu L; He N; Shi B; Hou P
    BMC Cancer; 2012 Feb; 12():50. PubMed ID: 22292935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
    Fang WL; Huang KH; Lan YT; Lin CH; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Li AF; Wu CW; Chiou SH; Shyr YM
    Oncotarget; 2016 Feb; 7(5):6201-20. PubMed ID: 26701847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
    Byun DS; Cho K; Ryu BK; Lee MG; Park JI; Chae KS; Kim HJ; Chi SG
    Int J Cancer; 2003 Apr; 104(3):318-27. PubMed ID: 12569555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
    Ito C; Nishizuka SS; Ishida K; Uesugi N; Sugai T; Tamura G; Koeda K; Sasaki A
    J Surg Res; 2017 May; 212():195-204. PubMed ID: 28550907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer.
    Yang Q; Shao Y; Shi J; Qu Y; Wu K; Dang S; Shi B; Hou P
    Clin Biochem; 2014 Jan; 47(1-2):111-6. PubMed ID: 24505629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
    Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
    BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
    Wu G; Mambo E; Guo Z; Hu S; Huang X; Gollin SM; Trink B; Ladenson PW; Sidransky D; Xing M
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4688-93. PubMed ID: 15928251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
    Harada K; Baba Y; Shigaki H; Ishimoto T; Miyake K; Kosumi K; Tokunaga R; Izumi D; Ohuchi M; Nakamura K; Kiyozumi Y; Kurashige J; Iwatsuki M; Miyamoto Y; Sakamoto Y; Yoshida N; Watanabe M; Baba H
    BMC Cancer; 2016 Jul; 16():400. PubMed ID: 27388016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.
    Zhou XK; Tang SS; Yi G; Hou M; Chen JH; Yang B; Liu JF; He ZM
    World J Gastroenterol; 2011 Aug; 17(32):3700-8. PubMed ID: 21990951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
    Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
    Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without
    Fang WL; Huang KH; Chang SC; Lin CH; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
    Oncologist; 2019 Sep; 24(9):e845-e853. PubMed ID: 30796154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
    Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
    Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
    Liu JF; Zhou XK; Chen JH; Yi G; Chen HG; Ba MC; Lin SQ; Qi YC
    World J Gastroenterol; 2010 Oct; 16(39):4986-91. PubMed ID: 20954287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.